Please assess the completion status of the following clinical trial:

Trial Title: Maternal Flu Vaccine Trial in Bamako, Mali

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women in third trimester of pregnancy (≥ 28 weeks gestational age based upon last menstrual period, ultrasound or uterine height).~2. Subject is able to understand and comply with planned study procedures.~3. Subject has provided written informed consent prior to initiation of any study procedures.~4. Subject intends to reside in the study area until her newborn infant is 6 months of age.~Exclusion Criteria:~1. Member of a household which already has a woman who is participating or has participated in this study~2. History of severe reactions following previous immunization with influenza or meningococcal vaccines~3. History of Guillain-Barré Syndrome~4. Known allergy or hypersensitivity to eggs, egg proteins, latex, diphtheria toxoid, or any other components of Vaxigrip and Menactra~5. Known chronic medical condition that in the judgment of the investigator could compromise the evaluation of the study vaccine or puts the subject at risk~6. Known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~7. Any of the following complications with the ongoing pregnancy: preterm labor (with cervical change), placental abruption, premature rupture of membranes, known major congenital anomaly, or preeclampsia.~8. Acute illness and/or an oral temperature greater than or equal to 37.8 degrees C, within 72 hours of vaccination (This may result in a temporary delay of vaccination)~9. Receipt of any other vaccine, excluding tetanus toxoid, within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines and meningococcal A conjugate vaccine (MenAfriVac)) prior to vaccination in this study~10. Woman who intends to travel out of the study area for the 40 days after delivery~11. Receipt of immunoglobulins and/or any blood products within 30 days prior to the administration of study vaccines~12. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying agents within 90 days prior to administration of study vaccines (including systemic corticosteroids, e.g. prednisone or equivalent \> 0.5 mg/kg/day; topical and inhaled steroids are allowed)~13. Any condition which in the opinion of the investigator might compromise the well-being of the participant or compliance with study procedures or interfere with the evaluation of the study vaccines

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Inactivated Influenza Vaccine Trivalent Types A and B (Type: EXPERIMENTAL): Women will be vaccinated with Influenza vaccine: Inactivated Influenza Vaccine Trivalent Types A and B
- Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate (Type: ACTIVE_COMPARATOR): Women will be vaccinated with IM injection of Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete